Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.
Izurieta HS, Wu X, Forshee R, Lu Y, Sung HM, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, MaCurdy TE, Kelman J, Dooling K.
Izurieta HS, et al. Among authors: lu y.
Clin Infect Dis. 2021 Sep 15;73(6):941-948. doi: 10.1093/cid/ciab125.
Clin Infect Dis. 2021.
PMID: 33580242